NJK14047

NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180) -induced psoriasis in mice[1].

Product Specifications

CAS Number

[1800576-41-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/njk14047.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC(C2=CC=C(C(C3=CC=C(OCC(O)CO)C=C3)=O)C=C2)=C(C)C=C1)NC4CC4

Molecular Formula

C27H27NO5

Molecular Weight

445.51

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800.